Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

• Status: Completed
• Trial end date: 2012-10-01

Summary

To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.

• Phase: Phase 2

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Medarex
• Treatments: Antibodies, Monoclonal; BB 1101; Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Cortisol succinate; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Fludrocortisone; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Ipilimumab; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prednisone; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide